Genelux (GNLX) investor relations material

Executive summary

• Focused on developing oncolytic viral immunotherapies for aggressive cancers, with lead candidate Olvi-Vec in late-stage clinical trials and topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer trial expected in 2H26.

• Net loss of $8.9 million for Q1 2026, up from $7.5 million in Q1 2025; accumulated deficit reached $292.5 million.

• Completed an underwritten public offering in January 2026, raising $18.5 million in net proceeds.

• Cash, cash equivalents, restricted cash, and marketable securities totaled $26.3 million as of March 31, 2026, expected to fund operations into Q1 2027.

• Manufacturing and operational capabilities are being strengthened for potential commercial readiness.

Financial highlights

• Revenue for Q1 2026 was $0; no product sales to date.

• Research and development expenses increased to $5.8 million (from $4.7 million in Q1 2025), mainly due to higher clinical trial costs and employee compensation.

• General and administrative expenses rose to $3.4 million (from $3.1 million), driven by higher employee compensation.

• Operating loss widened to $9.2 million from $7.8 million year-over-year.

• Net loss per share (basic and diluted) was $(0.20) for Q1 2026, compared to $(0.21) for Q1 2025.

Outlook and guidance

• Existing cash and marketable securities expected to fund operations into the first quarter of 2027.

• Additional clinical updates from lung cancer trials anticipated throughout 2026.

• Focus remains on advancing registration-directed programs and preparing for potential commercialization.

• Additional funding will be required to achieve business objectives beyond Q1 2027.